As international COVID-19 vaccination rates remain slow, some public health officials are worried more contagious variants are proliferating quickly enough that herd immunity won’t reduce the risk they pose.
BioNTech said it “has developed a comprehensive strategy to address these variants should the need arise in the future.” For example, the FDA has approved plans made by BioNTech and Pfizer to study the effectiveness of a third vaccine dose for prolonged immunity and protection against variants.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
